Teva Q3 revenue falls 8% to $3.6B; non-GAAP EPS $0.59 flat; opioid settlement progress

TEVA PHARMACEUTICAL INDUSTRIES LTD

2022-Q3 EPS reported -$1.02 revenue$11,041,000,000

Revenue $3.595B (-8% YoY, -2% in local currency); GAAP EPS $0.05; non-GAAP EPS $0.59 (flat YoY).
2022 revenue guidance cut to $14.8-15.4B (prev $15.0-15.6B) due to FX; all other guidance affirmed.
Opioid litigation: substantial progress toward nationwide settlement; agreement in principle with NY AG; reserve updated.
AUSTEDO U.S. revenue +30% YoY, on track for ~$1B annual; AJOVY gains share in U.S., Europe, Japan.
Cash from operations $543M; free cash flow $685M; non-GAAP tax rate outlook revised to 12-14%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended September 30, 2022 results: revenue $3,595 million, net income GAAP diluted EPS of $0.05, EPS Non-GAAP diluted EPS of $0.59. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $3,595 million
Net income: GAAP diluted EPS of $0.05
EPS: Non-GAAP diluted EPS of $0.59
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(EXHIBIT 99.1) --- EX-99.1 2 a52958636ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Teva Reports Third Quarter 2022 Financial Results Key financial highlights and outlook Revenues of $3.6 billion GAAP diluted EPS of $0.05 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $543 million Free cash flow of $685 million 2022 revenues outlook revised

View on SEC.gov

Browse all earnings releases →

TEVA PHARMACEUTICAL INDUSTRIES LTD filing history →

Source: SEC EDGAR

accession 0001157523-22-001500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.